Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4331-4340

  Rosenthal, Ian M ^a   Tasneen, Rokeya ^a   Peloquin, Charles A ^b   Zhang, Ming ^a   Almeida, Deepak ^a   Mdluli, Khisimuzi E ^c   Karakousis, Petros C ^a,d   Grosset, Jacques H ^a   Nuermberger, Eric L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; LUNG GRANULOMA; MONOTHERAPY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; ISONIAZID; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RANDOM ALLOCATION; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84864383796     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00912-12     Document Type: Article

References (56)

1. Almeida D, et al. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob.Agents Chemother. 53:4178-4184.
2. Blumberg HM, et al. 2003. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
3. British Thoracic and Tuberculosis Association. 1975. Short-course chemotherapy in pulmonary tuberculosis. Lancet i:119-124.
4. British Thoracic and Tuberculosis Association. 1976. Short-course chemotherapy in pulmonary tuberculosis. Lancet ii:1102-1104.
5. Burman WJ, Gallicano K, Peloquin C. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341. (Pubitemid 32565595)
6. Davies GR. 2010. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis (Edinb.) 90:171-176.
7. Davis SL, et al. 2009. Noninvasive pulmonary [18F]-2-fluoro-deoxy- Dglucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53:4879-4884.
8. Diacon AH, et al. 2007. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51:2994-2996. (Pubitemid 47206244)
9. Dooley KE, et al. 2012. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin. Pharmacol. Ther. doi:10.1038/clpt.2011.323.
10. Dorman S, et al. 2011. A phase II study of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis: preliminary results for Tuberculosis Trials Consortium Study 29. Am. J. Respir. Crit. Care Med. 183:A6413.
11. Dutta NK, et al. 30 April 2012, posting date. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob. Agents Chemother. doi:10.1128/AAC.00500-12.
12. East and Central African and British Medical Research Councils. 1986. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 67:5-15.
13. East and Central African and British Medical Research Councils. 1973. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet i:1331-1338.
14. Gagneux S, et al. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946. (Pubitemid 43993719)
15. Grosset J. 2003. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob. Agents Chemother. 47:833-836. (Pubitemid 36254203)
16. Grosset J, et al. 1998. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am. J. Respir. Crit. Care Med. 157:1436-1440.
17. Grosset JH, Rosenthal I, Zhang M, Williams K, Nuermberger EL. 2008. Low doses of rifapentine versus high doses of rifampin in the mouse model of tuberculosis. Int. J. Tuberc. Lung Dis. 12(11 Suppl. 2):S63.
18. Grosset JHE, Rosenthal IM, Zhang M, Nuermberger EL. 2008. Doseranging comparison of rifampin and rifapentine in combination with isoniazid and pyrazinamide in the mouse model of tuberculosis, abstr. A-1825. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
19. Gumbo T, et al. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788. (Pubitemid 350057771)
20. Harper J, et al. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205:595- 602.
21. Hunter RL, Jagannath C, Actor JK. 2007. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb.) 87:267-278. (Pubitemid 46951032)
22. Jayaram R, et al. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124. (Pubitemid 36753560)
23. Jindani A, Aber VR, Edwards EA, Mitchison DA. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949. (Pubitemid 10118376)
24. Kenny MT, Strates B. 1981. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab. Rev. 12:159-218. (Pubitemid 12208844)
25. Keung A, Eller MG, McKenzie KA, Weir SJ. 1999. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int. J. Tuberc. Lung Dis. 3:437-444. (Pubitemid 29294695)
26. Keung A, et al. 1999. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steadystate rifapentine pharmacokinetics: part I. Int. J. Tuberc. Lung Dis. 3:426-436. (Pubitemid 29294694)
27. Kjellsson MC, et al. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56:446-457.
28. Kochar DK, et al. 2006. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J. Vector Borne. Dis. 43:161-167. (Pubitemid 44901458)
29. Lenaerts AM, Chase SE, Chmielewski AJ, Cynamon MH. 1999. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrob. Agents Chemother. 43:2356-2360. (Pubitemid 29471209)
30. Mor N, Simon B, Mezo N, Heifets L. 1995. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077.
31. Nuermberger E. 2008. Using animal models to develop new treatments for tuberculosis. Semin. Respir. Crit. Care Med. 29:542-551.
32. Nuermberger E, et al. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50:2621-2625. (Pubitemid 44198679)
33. Nuermberger EL, et al. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134. (Pubitemid 39488628)
34. Pan H, et al. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772. (Pubitemid 44739520)
35. Peloquin C. 2003. What is the 'right' dose of rifampin? Int. J. Tuberc. Lung Dis. 7:3-5. (Pubitemid 36427025)
36. Peloquin CA, et al. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:2670-2679. (Pubitemid 27524738)
37. Peloquin CA, Namdar R, Singleton MD, Nix DE. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18. (Pubitemid 29047048)
38. Rosenthal IM, Zhang M, Grosset JH, Nuermberger EL. 2008. Rifapentine-containing regimens cure murine tuberculosis in weeks rather than months. Am. J. Respir. Crit. Care Med. 177:A789.
39. Rosenthal IM, et al. 2006. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am. J. Respir. Crit. Care Med. 174:94-101. (Pubitemid 43955249)
40. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178:989 -993.
41. Rosenthal IM, et al. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. doi: 10.1371/journal.pmed.0040344.
42. Ruslami R, et al. 2007. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51:2546 -2551.
43. Singapore Tuberculosis Service and British Medical Research Council. 1981. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 62:95-102.
44. Solera J, et al. 1995. Doxycycline-rifampin versus doxycyclinestreptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob. Agents Chemother. 39:2061-2067.
45. Steingart KR, et al. 2011. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuberc. Lung Dis. 15:305-316.
46. Tasneen R, et al. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:5485-5492.
47. Tasneen R, Peloquin C, Nuermberger E. 2011. Dose-ranging activity of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis, abstr. O-15. Progr. Abstr. Fourth Int. Workshop Clin. Pharmacol. Tuberc. Drugs, Chicago, IL. Virology Education B.V., Utrecht, The Netherlands.
48. Telenti A, et al. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647- 650.
49. Verbist L. 1969. Rifampicin activity "in vitro" and in established tuberculosis in mice. Acta Tuberc. Pneumol. Belg. 60:397- 412.
50. Verbist L. 1971. Pharmacological study of rifampicin after repeated high dosage during intermittent combined therapy. I. Variation of the rifampicin serum levels (947 determinations). Respiration 28(Suppl.):7-16.
51. Weiner M, et al. 2010. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob. Agents Chemother. 54:4192- 4200.
52. Weiner M, et al. 2011. Rifapentine exposure in a trial of daily rifapentine compared to rifampin during the intensive phase of TB treatment. Am. J. Respir. Crit. Care Med. 183:A6341.
53. Wilkins JJ, et al. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148. (Pubitemid 351758551)
54. Williams KN, et al. 2009. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med. 180:371-376.
55. Zhang M, et al. 2011. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183:1254 -1261.
56. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. 2011. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 184:732-737.